Show simple item record

dc.contributor.authorZurovac, D.en_US
dc.contributor.authorNjogu, J.en_US
dc.contributor.authorAkhwale, W.en_US
dc.contributor.authorHamer, D. H.en_US
dc.contributor.authorSnow, R. W.en_US
dc.date.accessioned2012-01-09T21:04:10Z
dc.date.available2012-01-09T21:04:10Z
dc.date.issued2008-01
dc.identifier.citationZurovac, D, J Njogu, W Akhwale, D H Hamer, R W Snow. "Translation of artemether-lumefantrine treatment policy into paediatric clinical practice: an early experience from Kenya" Tropical Medicine & International Health 13(1): 99-107. (2008)
dc.identifier.issn1365-3156
dc.identifier.urihttps://hdl.handle.net/2144/2992
dc.description.abstractOBJECTIVE. To describe the quality of outpatient paediatric malaria case-management approximately 4-6 months after artemether-lumefantrine (AL) replaced sulfadoxine-pyrimethamine (SP) as the nationally recommended first-line therapy in Kenya. METHODS. Cross-sectional survey at all government facilities in four Kenyan districts. Main outcome measures were health facility and health worker readiness to implement AL policy; quality of antimalarial prescribing, counselling and drug dispensing in comparison with national guidelines; and factors influencing AL prescribing for treatment of uncomplicated malaria in under-fives. RESULTS. We evaluated 193 facilities, 227 health workers and 1533 sick-child consultations. Health facility and health worker readiness was variable: 89% of facilities stocked AL, 55% of health workers had access to guidelines, 46% received in-service training on AL and only 1% of facilities had AL wall charts. Of 940 children who needed AL treatment, AL was prescribed for 26%, amodiaquine for 39%, SP for 4%, various other antimalarials for 8% and 23% of children left the facility without any antimalarial prescribed. When AL was prescribed, 92% of children were prescribed correct weight-specific dose. AL dispensing and counselling tasks were variably performed. Higher health worker's cadre, in-service training including AL use, positive malaria test, main complaint of fever and high temperature were associated with better prescribing. CONCLUSIONS. Changes in clinical practices at the point of care might take longer than anticipated. Delivery of successful interventions and their scaling up to increase coverage are important during this process; however, this should be accompanied by rigorous research evaluations, corrective actions on existing interventions and testing cost-effectiveness of novel interventions capable of improving and maintaining health worker performance and health systems to deliver artemisinin-based combination therapy in Africa.en_US
dc.description.sponsorshipThe Wellcome Trust; the Kenya Medical Research Institute; Novartis Pharmaen_US
dc.language.isoen
dc.publisherBlackwell Publishing Ltden_US
dc.subjectMalariaen_US
dc.subjectChange of treatmenten_US
dc.subjectSulfadoxine-pyremethamineen_US
dc.subjectArtemether-lumefantrineen_US
dc.subjectHealth facility evaluationen_US
dc.subjectKenyaen_US
dc.titleTranslation of Artemether-Lumefantrine Treatment Policy into Paediatric Clinical Practice: An Early Experience from Kenyaen_US
dc.typeArticleen_US
dc.identifier.doi10.1111/j.1365-3156.2007.01980.x
dc.identifier.pmid18291008
dc.identifier.pmcid2592474


This item appears in the following Collection(s)

Show simple item record